Stratrix
Competitors · Icon

Who are Icon’s competitors?

Icon names 6 companies as competitors in its latest annual report. 2 companies name Icon back.

Skip to the field, head to head ↓Icon company profile

Competitors it names620-F for fiscal 2025
Companies that name it2in their own annual reports
Revenue, 2025$8.3B+1% on a year
Net margin3%Iqvia 8% · Fortrea −36%
Stratrix’s Take

ICON's scale is real, but Medpace, at $2.5 billion, grows faster and keeps more

ICON took in $8.3 billion in 2025. Only IQVIA, at $16.3 billion, is larger among the companies here. ICON says it competes primarily with IQVIA and others for "large development programs". Size is the ground it has chosen to fight on.

Size did not show up in the results. ICON grew 1% with a 3% net margin. IQVIA grew 6% with 8%. Medpace grew 20% with 18% on a base less than a third of ICON's. Fortrea also grew 1%, but its net margin was -36%. ICON is not in trouble. It is just not being paid for its scale.

Its customer base is not the weak point. The top five customers made up 24.8% of revenue, against 25.2% a year earlier, and the largest was 7.0%. The idea to repeat: ICON is built to be hard to lose, and has not yet shown it can grow fast or earn more.

The fronts

Where Icon says it competes

Large development program competitors
IQVIAPAREXELPPD clinical research services brand of Thermo Fisher ScientificFortreaSyneos Health
“When competing for large development programs, ICON competes primarily with IQVIA, PAREXEL, the PPD clinical research services brand of Thermo Fisher Scientific Inc., Fortrea and Syneos Health.”
In its own words · 20-F for fiscal 2025
Also named
Thermo Fisher Scientific
Named back

Who names Icon as a competitor

“Our major CRO competitors include IQVIA Holdings Inc., ICON plc, PPD, Inc. (now part of Thermo Fisher Scientific Inc.), Fortrea, Inc., and numerous specialty and regional CROs.”

10-K for 2025

“Our Data and applications products also face competition from CROs, such as Fortrea, ICON, Syneos, PPD, and others, who provide data and clinical trial matching services to pharmaceutical and biotechnology companies.”

10-K for 2025
Head to head

The field, from the filings

CompanyFiscal yearRevenueGrowthNet marginEmployees
Icon2025$8.3B+1%3%40,100
Iqvia2025$16.3B+6%8%93,000
Fortrea2025$2.7B+1%−36%14,300
Medpace Holdings2025$2.5B+20%18%6,200
Tempus AI2025$1.3B+83%−19%3,800

Each company’s latest fiscal year as reported to the SEC, in US dollars; fiscal years end in different months. Rivals that report outside the US or in other currencies are not shown.

Customers

How concentrated Icon’s customers are

“Customers Duri ng the year ended December 31, 2025, revenue was earned from a wide range of customers and 24.8% of our revenues were derived from our top five customers, with no one customer individually contributing more than 10% of our revenues during the period.”
In its own words · 20-F for fiscal 2025
“Our largest customer represented a strategic partnership with a large global pharmaceutical company and contributed 7.0% of revenue for the year.”
In its own words · 20-F for fiscal 2025
“During the year ended December 31, 2024, 25.2% (as restated) of our revenues were derived from our top five customers, with no one customer individually contributing more than 10% of our revenues during the period.”
In its own words · 20-F for fiscal 2025
The moves

What the rivals have done lately

Tempus AIAcquired SEngine Precision Medicine

“SEngine Precision Medicine LLC (including its predecessor corporation SEngine Precision Medicine, Inc.), or SEngine, a company we acquired on October 3, 2023, received a letter from an attorney representing HUB Organoids IP B.V., or HUB …” filing

Tempus AIAcquired OneOme

“Our acquisition of OneOme, Inc., or OneOme, in November 2025 further enhanced our ability to provide pharmacogenetics tests, such as DPYD.” filing

Questions

Asked about Icon’s competitors

Who are Icon's competitors?

In its annual report for fiscal 2025, Icon names 6 competitors. 20-F for fiscal 2025

Which companies name Icon as a competitor?

2 companies in our coverage name it in their own annual reports: Medpace Holdings and Tempus AI.

How does Icon compare with its rivals?

Icon reported $8.3B in revenue in its latest fiscal year, +1% on a year, with a 3% net margin. Iqvia: $16.3B, 8% net margin; Fortrea: $2.7B, −36% net margin.

What are the alternatives to Icon?

The companies Icon itself names as competitors are listed above, front by front, each in its own report’s words. Which matters for a given buyer depends on the job, not the list.

Is your best customer building your replacement?

How much of your revenue comes from somebody who is also trying to replace you?

See the pack →

Sources: Icon’s annual report for fiscal 2025; the annual reports of the companies that name it; each company’s financial data as reported to the SEC; Stratrix Decision Records. Analysis and data, not advice.

For information and strategic analysis only, not investment advice. Stratrix does not recommend buying, selling or holding any security.

Tools to try

More from Stratrix

The Business Model Wizard

Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.

Free · about twelve minutesBuild your Model Thesis →

Weekly email

Stratonomics, every Tuesday

One data story every Tuesday: what happened, what it means, and the figures you can quote. Free.

We'll email you a link to confirm. Unsubscribe anytime. Privacy policy.